






INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification⁴ : C07H 19/10, 19/06, 19/073 C07H 23/00</p>	<p>A1</p>	<p>(11) International Publication Number: WO 88/ 10264</p> <p>(43) International Publication Date: 29 December 1988 (29.12.88)</p>
<p>(21) International Application Number: PCT/AU88/00207</p> <p>(22) International Filing Date: 24 June 1988 (24.06.88)</p> <p>(31) Priority Application Number: PI 2666</p> <p>(32) Priority Date: 24 June 1987 (24.06.87)</p> <p>(33) Priority Country: AU</p> <p>(71) Applicant (for all designated States except US): HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE [AU/AU]; The University of Melbourne, Grattan Street, Parkville, VIC 3052 (AU).</p> <p>(72) Inventor; and (75) Inventor/Applicant (for US only) : HARALAMBIDIS, Jim [AU/AU]; 156 Elgar Road, Box Hill South, VIC 3128 (AU).</p>		<p>(74) Agents: CORBETT, Terence, Guy et al.; Davies & Collison, 1 Little Collins Street, Melbourne, VIC 3000 (AU).</p> <p>(81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US.</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>

(54) Title: NUCLEOSIDE DERIVATIVES



(57) Abstract

A nucleoside derivative of formula (I), characterized in that: Y is H or OH or a protected hydroxy group; X is H, a phosphonate group or a phosphoramidite group of formula (II), where R¹ and R² are the same or different, and are selected from alkyl and substituted alkyl, which may be branched or unbranched; and Q is a phosphate protecting group; Z is H, a phosphate or triphosphate group or a hydroxy protecting group; X' is a C₁₋₁₅ alkyl group which may be branched or unbranched; R is an amino protecting group or a fluorophore, or other non-radioactive detectable marker; or the group Y'NHA, where Y' is an alkyl (C₁₋₄₀) carbonyl group which may be branched or unbranched, and A is an amino protecting group or a fluorophore or other non-radioactive detectable marker. Methods for the synthesis and sequencing of polynucleotides utilizing compounds of formula (I).

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

- 1 -

NUCLEOSIDE DERIVATIVES

The present invention relates to nucleoside derivatives, methods for their synthesis, and methods for the synthesis and sequencing of polynucleotides utilizing such nucleoside derivatives.

5 [NOTE: References cited herein are collected at the end of the specification.]

DNA, synthetic oligonucleotides and RNA labelled with identifiable markers have found wide application in molecular biology.

10 Radioactive labels, such as ^{32}P and ^{35}S have been almost exclusively used in molecular biological procedures. Radioactive labels have the disadvantage, however, that their half life is relatively short (for example, the half life of ^{32}P
15 is 14 days) and that the ionizing radiation emitted during their decay is capable of damaging cellular components such as proteins, lipids and nucleic acids, which may result in cell death, or

20

- 2 -

transformation of cells to malignant forms.

It has been proposed to label nucleotides or oligonucleotides with non-radioactive markers such as fluorophores, colloidal compounds and enzymes.

5 In one proposed approach¹, oligonucleotides containing a reactive amino group at the 5' end were prepared. Fluorophores or other non-radioactive markers were then attached to the amino group to produce an oligonucleotide incorporating a detectable
10 marker. Such an approach has the disadvantage that only a single detectable marker can be introduced into the oligonucleotide chain through its 5' end.


In another proposal²⁻⁵, C-5 substituted deoxyuridine compounds have been prepared, which have
15 an amino group at the far end of the C-5 substituent. Such compounds may be labelled with a detectable marker and may be incorporated into an oligonucleotide chain, thereby allowing an oligonucleotide to be labelled at multiple sites.
20 The preparation of these compounds is difficult and involves reactions using highly toxic mercury derivatives.

There is thus a need for nucleoside derivatives which may be used in the production of
25 non-isotopically labelled polynucleosides, and which may be simply and safely prepared.

According to the present invention there is provided a nucleoside derivative of the formula (I):

30

- 3 -




characterized in that;

Y is H or OH or a protected hydroxy group;

X is H, a phosphonate group or a phosphoramidite group of the formula

15



where R^1 and R^2 are the same or different, and are selected from alkyl and substituted alkyl, which may be branched or unbranched; and Q is a phosphate protecting group;

20

Z is H a phosphate or triphosphate group or a hydroxy protecting group;

25

X' is a C_{1-15} alkyl group which may be branched or unbranched;

R is an amino protecting group or a fluorophore, or other non-radioactive detectable marker; or the group Y'NHA, where Y' is an alkyl (C_{1-40}) carbonyl group which may be branched or unbranched, and A is an amino protecting group or a fluorophore or other non-radioactive detectable marker.

30

- 4 -

For ease of discussion, Figure 1, which depicts one preferred compound in accordance with the invention, also shows the numbering system used in this specification for the C-5 substituted nucleosides.

We have found that C-5 substituted uridine and deoxyuridine, having a primary aliphatic amino group attached to, or capable of attachment to, a non-radioactive label, can be readily prepared under mild conditions, using a palladium catalysed C-C bond forming reaction between an aminoalkyne and 5-iodouridine or 5-iododeoxyuridine derivatives.

R^1 and R^2 may each contain from 1 to 30 carbon atoms. Preferably, R^1 and R^2 are both isopropyl groups. Where R^1 and/or R^2 are substituted alkyl, the nature of the substituents is unimportant providing the substituents do not interfere with the desired properties of the compound or have other deleterious effects. For example, the substituents may be selected from phenyl, benzyl and acyl groups.

Q may be any phosphate protecting group such as methyl, phenyl, substituted phenyl, benzyl or cyanoethyl groups. For example, phenyl may be substituted with halogen, hydroxy or nitro groups.

Any hydroxy protecting group, such as those described by Greene⁶, may be employed. For example, hydroxy protecting groups may be selected from acyl such as substituted or unsubstituted alkanoyl (e.g. formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, bromoacetyl, dichloroacetyl, trifluoroacetyl), substituted or unsubstituted aroyl (e.g. benzoyl, toluoyl, xyloyl, nitrobenzoyl, bromobenzoyl, salicyloyl), arylalkyl (e.g. benzyl),

- 5 -

methyl, methoxy, methylthiomethyl, 2-methoxyethoxy-methyl, bis(2-chloroethoxy)methyl, tetrahydropyranyl, tetrahydrothiopyranyl, 4-methoxytetrahydropyranyl, 4-methoxytetrahydrothiopyranyl, tetrahydrofuranyl, 5 tetrahydrothiofuranyl, 1-ethoxyethyl, 1-methyl-1-methoxyethyl 2-(phenylselenyl)ethyl, t-butyl, allyl, benzyl, o-nitrobenzyl, triphenylmethyl, α -naphthyl-diphenylmethyl, p-methoxyphenyldiphenylmethyl, 9-(9-phenyl-10-oxo)anthryl (Tritylone), dimethoxy 10 trityl or pixyl, trimethylsilyl, isopropyl-di-methylsilyl, t-butyl-di-methylsilyl, t-butyl-diphenylsilyl, tribenzylsilyl, triisopropylsilyl.

Any amino protecting group such as those described by Greene⁶, may be employed. For 15 example, amino protecting groups may be selected from acyl, particularly organic acyl, for example, substituted or unsubstituted aliphatic hydrocarbon-oxycarbonyl such as

alkoxycarbonyl (e.g. methoxycarbonyl, 20 ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, t-butoxycarbonyl, 5-pentoxycarbonyl),

haloalkoxycarbonyl (e.g. chloromethoxycarbonyl, tribromoethoxycarbonyl, trichloroethoxycarbonyl),

an alkane- or arene- sulfonylalkoxycarbonyl (e.g. 25 2-(mesyl)ethoxycarbonyl, 2-(p-toluenesulonyl)-ethoxycarbonyl),

an alkylthio- or arylthioalkoxycarbonyl (e.g. 2-(ethylthio)ethoxycarbonyl, 2-(p-tolylthio)ethoxy-carbonyl), substituted or unsubstituted alkanoyl 30 such as halo(lower)alkanoyl (e.g. formyl, trifluoroacetyl),

a monocyclic or fusedcyclic-alicyclic oxycarbonyl (e.g. cyclohexyloxycarbonyl, adamantyloxycarbonyl,

- 6 -

- isobornyloxy carbonyl),
substituted or unsubstituted alkenyloxy carbonyl
(e.g. allyloxy carbonyl),
substituted or unsubstituted alkynyloxy carbonyl
5 (e.g. 1,1-dimethylpropargyloxy carbonyl),
substituted or unsubstituted aryloxy carbonyl
(e.g. phenoxy carbonyl, p-methylphenoxy carbonyl),
substituted or unsubstituted aralkoxy carbonyl
(e.g. benzyloxy carbonyl, p-nitrobenzyloxy carbonyl,
10 p-phenylazobenzyloxy carbonyl, p-(p-methoxyphenylazo)-
benzyloxy carbonyl, p-chlorobenzyloxy carbonyl,
p-bromobenzyloxy carbonyl, α -naphthylmethoxy car-
bonyl, p-biphenylisopropoxy carbonyl, fluorenylmethoxy-
carbonyl),
15 substituted or unsubstituted arenesulfonyl (e.g.
benzenesulfonyl, p-toluenesulfonyl),
substituted or unsubstituted dialkylphosphoryl
(e.g. dimethylphosphoryl),
substituted or unsubstituted diaralkylphosphoryl
20 (e.g. O,O-dibenzylphosphoryl),
substituted or unsubstituted aryloxyalkanoyl
(e.g. phenoxyacetyl, p-chlorophenoxyacetyl,
2-nitrophenoxyacetyl, 2-methyl-2-(2-nitro-
phenoxy)propionyl)
25 substituted or unsubstituted aryl such as phenyl,
tolyl;
substituted or unsubstituted aralkyl such as
benzyl, diphenylmethyl, trityl or nitrobenzyl.

The term "fluorophore" refers to a moiety which
30 in itself is capable of fluorescence or which confers
fluorescence on another moiety. As used in this
specification the term "fluorophore" also refers to a
fluorophore precursor which contains one or more
groups which suppress fluorescence, but which is

- 7 -

12/02/2003, EAST Version: 1.4.1

- 8 -

substances have the following spectroscopic properties:

- (i) an excitation maximum coinciding with one of the strong emission lines of the commercially used high pressure mercury lamps;
- (ii) an emission maximum in the visible part of the spectrum.

Non-radioactive detectable markers include entities which may be detected directly by their physical properties, such as electron dense materials which can be detected under a microscope; or entities which may be detected indirectly by their chemical or biochemical properties, such as by the reaction of the detectable marker with a suitable substrate(s) to produce a detectable signal, such as colour.

Examples of non-radioactive detectable markers which may be detected directly includes colloidal compounds such as colloidal gold and silver, and ferritin.


Examples of non-radioactive detectable markers which may be detected indirectly include biotin, avidin and enzymes such as β -galactosidase, urease, peroxidase and alkaline phosphatase.

X' is preferably CH_2
R is preferably $\text{CO}(\text{CH}_2)_{1-15} \text{A}$ and more preferably $\text{CO}(\text{CH}_2)_5 \text{A}$.

Particularly preferred compounds of formula (I) have the following substituents:

30


- 9 -

	Y	X	Z	X'	R
5	DH		DMTr	CH ₂	$\text{CH}(\text{O})-(\text{CH}_2)_5\text{NHA}$
	H	"	DMTr	CH ₂	"
	OH	H	DMTr	CH ₂	"
	H	H	Triphosphate	CH ₂	"

where the group A is as defined above, and DMTr refers to dimethoxy trityl, and D is a hydroxy protecting group.

The compounds of the formula (I) may be prepared by reacting a 5-iodouridine or 5-iododeoxyuridine of the formula:

15



(I)

20

wherein X and Z are as previously defined in claim 1;


25 with an aminoalkyne having the formula $\text{H}-\text{C}\equiv\text{CX}'\text{NR}$, where X' and R are as previously defined, in the presence of a palladium catalyst.

More particularly, compounds of the formula (I) may be prepared according to the following steps:

30


(A) Reacting a compound of the formula (1):

- 10 -




where B and B' are hydroxy protecting groups which may be the same or different, and Y is as previously defined;

with $\text{H}-\text{C}\equiv\text{C}-\text{X}'\text{NR}$, where X' and R are as defined previously, in the presence of $(\text{Ph}_3\text{P})_2\text{PdCl}_2$ and CuI , at room temperature to form:




(B) Removing the protecting groups B and B' from compounds of the formula (2) to form:




Compounds of formula (3) may be converted into other compounds, in accordance with the invention, by further reactions.

- 11 -

- (C) Compound (3) may be reacted with a compound of the formula B"A', where B" is a protecting group such as any derivative of the trityl group, and A' is a leaving group to form:




- 15 (D) Compound (4) may be reacted with a compound of the formula XR', where R' is a leaving group and X is as previously defined, to form:



- 25
- (E) Compound (5) may be reacted with, for example, either an acid or base depending on whether protecting group B" is acid or base labile to effect removal of the group B", and then reacted with POCl₃ in the presence of triethylphosphate to form:
- 30


- 12 -



10

(F) Compound (6) may be reacted first with carbonyldiimidazole and then with tris(tetra- butylammonium)pyrosphate or tributylammonium- pyrophosphate to form:

15




25 Compound (7) which is one of a preferred class of compounds of the invention may, by virtue of its 5'triphosphate group be purified by ion-exchange chromatography, reverse phase chromatography or cellulose chromatography.

30 Any conventional leaving group R' may be employed in the above reaction (D). Examples of such groups are Cl, Br, I, p-nitrophenyloxy, pentafluorophenyloxy and diisopropylamino. B'' may be the same as B and B' or different. B'' may be selectively introduced to the 5'hydroxyl using standard techniques known per se

- 13 -


in the art.

The chain length of the C-5 substituent of compounds of the formula (2), where R is an amino protecting group such as BOC, may be extended by treatment with acid to remove the group R, followed by reaction with an active ester of the type



where R is an amino protecting group, n is from 1 to 50 and E is a good leaving group (known per se in the art) such as p-nitrophenyloxy or pentafluorophenyloxy, in the presence of (1,8-diazacyclo[4.4.0]undec-7-ene) DBU to form

15



20

This process may be carried out as many times as desired to increase the chain length of the carbon 5 substituent.


As the skilled person will readily appreciate, in compounds of the formula (I) where the groups R or A are an amino protecting group, such as BOC; the protective group may be removed under appropriate conditions, and a fluorophore or other non-radioactive marker reacted with the free amino group, thereby producing a nucleoside derivative which is labelled with a fluorophore or other

- 14 -

non-radioactive marker.

Polynucleotides may be prepared using compounds of the formula (I).

According to another aspect of the invention,
 5 there is provided a polynucleotide, characterized in that it contains one or more nucleotide units of the formula (III)



wherein X', Y and R are as previously defined.

The nucleotide unit (III) depicts a compound of
 20 the formula (I) incorporated in a polynucleotide chain.

Compounds of the formula (I) may be incorporated into cDNA, synthetic oligonucleotides and RNA using standard procedures^{7, 8-12}.


25 According to a further aspect of the invention there is provided a method for the synthesis of a polynucleotide wherein individual nucleotides or groups of nucleotides are sequentially attached to a growing nucleotide chain, characterized in that at
 30 least one of the nucleotides is a nucleoside derivative of the formula (I) as previously defined.

More particularly, polynucleotides which contain one or more nucleotide derivatives of the formula (III) may be prepared by reacting together:

- 15 -

- (a) a first polynucleotide;
 (b) a second polynucleotide which hybridises to a portion of the first polynucleotide;
 (c) one or more nucleotide triphosphates;
 5 (d) a DNA polymerase or RNA polymerase;
 whereby a polynucleotide is synthesised from the 3' end of said second polynucleotide, characterised in that at least one of said nucleotide triphosphates is a nucleoside derivative of the formula (I) wherein
 10 Z is triphosphate and X is hydrogen.

Polynucleotides which contain one or more nucleoside derivatives may also be prepared, in accordance with another aspect of the invention, by sequentially coupling nucleotides together through
 15 their respective 5' and 3' ends, characterised in that at least one of said nucleotides is a nucleoside derivative of the formula (I) wherein X is selected from phosphonate or a group of the formula



wherein R^1 , R^2 and Q are as previously defined.

Compounds of the formula (I) may be incorporated into synthetic oligonucleotides using standard
 25 phosphotriester chemistry¹⁹.


For incorporation into RNA, the compounds of the formula (I) have a 5' triphosphate group, and hydroxyl groups at the 3' and 2' positions.

Polynucleotides labelled at multiple sites may be
 30 produced according to one aspect of the invention. The effect of multiple labelling is advantageous, as the read-out signal is enhanced over that produced by polynucleotides labelled at a single position.

- 16 -

Where nucleoside derivatives of the formula (I) do not contain a fluorophore or non-radioactive detectable marker prior to incorporation into a polynucleotide, a detectable label may be subsequently introduced into the formed polynucleotide. For example, this may be done by removing a protecting group masking the aliphatic amino group on the C-5 substituent, and then reacting the thus produced amino groups with a fluorophore such as fluorescein-5-isothiocyanate.

Nucleosides containing non-fluorescent fluorophore analogues (fluorophore precursors) may be used in the preparation of polynucleotides. The use of fluorophore precursors avoid the possibility of fluorophore bleaching during the chemical manipulations necessary for the preparation of polynucleotides. Under appropriate conditions (for example, ammonia treatment) those groups on a fluorophore precursor which suppress fluorescence may be removed thus converting the fluorophore precursor to a fluorescent form. By way of example, a reaction scheme for the preparation of a nucleoside derivative of the formula (I) containing a non-fluorescent analogue of fluorescein is shown in Figure 2. The resultant compound B of Figure 2 has the following formula:



- 17 -

Compound B will fluoresce on removal of the iso-butyryl groups following ammonia treatment.

Compound B may be used in oligonucleotide synthesis (in a protected 5', 3' phosphoramidite form) or cDNA synthesis (in a 5'triphosphate form). A uridine analogue of the compound B may be used in RNA synthesis with T7 polymerase¹¹ or SP6 polymerase¹².

The compounds of the present invention are useful in molecular biological techniques which normally utilise isotopically labelled probes. Such techniques include DNA and RNA hybridizations such as dot blots, Southern blots, hybridization histochemistry, Northern blots and plaque hybridizations.

The nucleoside derivatives of the formula (I) or polydeoxynucleotides incorporating such nucleoside derivatives may be used in DNA sequencing reactions.

According to another aspect of the invention, there is provided a method of sequencing DNA which comprises the steps of:

- (a) providing a first reaction mixture comprising:
 - (i) a polydeoxynucleotide;
 - 25 (ii) a polydeoxynucleotide primer capable of hybridizing to part of the polydeoxynucleotide (i);
 - (iii) dATP, dGTP, dCTP, dTTP;
 - (iv) ddATP;
 - (v) a DNA polymerase or the Klenow fragment of DNA
- 30 polymerase;
- (b) providing a second reaction mixture which is the same as said first reaction mixture, except that the ddATP is replaced with ddGTP;
- (c) providing a third reaction mixture which is

- 18 -

the same as the said first reaction mixture except that ddATP is replaced with ddCTP;

(d) providing a fourth reaction mixture which is the same as the said first reaction mixture except
5 that the ddATP is replaced with ddTTP;

(e) separately incubating the said reaction mixtures to extend in each case the polydeoxynucleotide primer from its 3' end to produce polydeoxynucleotides of different lengths, the number
10 of nucleotides in each thereby newly synthesised polynucleotide being determined by the incorporation of a dideoxynucleotide into the growing chain;

(f) fractionating reaction mixtures (a) to (d) by passage through a gel matrix;

15 characterized in that the polydeoxynucleotide primer (ii) is a polydeoxynucleotide containing one or more nucleotide units of the formula (III) as previously described wherein R and A is a fluorophore, or other non-radioactive detectable
20 marker, and/or each said reaction mixture contains a nucleoside derivative of the formula (I), wherein Z is triphosphate, X is hydrogen, and R or A is a fluorophore, or other detectable marker; whereby the fluorophore, or other non-radioactive detectable
25 marker, is incorporated into each newly synthesized polydeoxynucleotide;

and that the relative positions of the newly synthesized polydeoxynucleotides separated on the gel matrix are identified by detection of the
30 fluorophore, or other non-radioactive detectable marker, carried by the newly synthesized polydeoxynucleotide, thus allowing the DNA sequence of the first polynucleotide to be elucidated.

The newly synthesized polynucleotides of step (e)

- 19 -

above may, for example, be detected by fluorescence induced by irradiation with a light source, such as a laser.

Each of reaction mixtures (a) to (d) above may contain a different fluorophore having different emission maxima, or a different non-radioactive detectable marker. That is, the oligonucleotide primer (ii) and/or the nucleoside derivative of the formula (I) in each of reaction mixtures (a) to (d) contains groups R or A having a distinct emission maxima.

Several embodiments of the present invention will now be described, by way of example only, with reference to the accompanying figures in which:

15 FIGURE 1 shows the numbering system for C-5 substituted nucleosides, used in this specification;

20 FIGURE 2 shows the preparation of nucleoside derivatives of the present invention incorporating a modified non fluorescent fluoroscein moiety;

25 FIGURE 3 shows the preparation of the short C-5 aminoalkyne nucleoside 2;

30 FIGURE 4 shows the preparation of the long C-5 arm nucleoside phosphoramidite 11;

FIGURE 5 shows the preparation of the long C-5 arm nucleoside phosphoramidite 11;

FIGURE 6 shows dot blot hybridization assays with the short C-5 arm fluorescently labelled kallikrein oligonucleotides to mouse salivary gland mRNA. The probes were ^{32}P end-labelled and hybridized as explained hereinafter. A, normal probe, high stringency conditions, 4 hr exposure; B, singly labelled probe, intermediate stringency, 4 hr exposure; C, normal probe, high stringency, 16 hr exposure; D, multi-labelled probe, low stringency 16

- 20 -

hr exposure; E, multi-labelled probe, lowest stringency, 16 hr exposure;

FIGURE 7 shows dot blot hybridization assays with the long C-5 arm fluorescently labelled kallikrein probe. The probes were ^{32}P end-labelled and hybridized under conditions of high stringency. Exposure times for the autoradiographs were 4 hr. A, normal probe; B, singly labelled probe; C, multi-labelled probe; and

FIGURE 8 shows dot blot hybridization assays with the ^{32}P end-labelled, singly fluorescent labelled kallikrein probes to three different RNA species. Hybridizations were carried out under conditions of intermediate stringency and exposure time for the autoradiographs was 16 hr. A, short C-5 arm probe; B, long C-5 arm probe.

MATERIALS AND METHODS

5-Iododeoxyuridine and fluorescein isothiocyanate (FITC) were obtained from Sigma Chemical Company.

^1H NMR spectra were run on either of JEOL FX90Q at 90 MHz, a JEOL FX100 at 100 MHz, or a BRUKER 300 at 300 MHz. ^{13}C NMR spectra were run on either a JEOL FX90Q operating at 22.5 MHz, a JEOL FX100 at 25 MHz, or a BRUKER 300 at 75 MHz. Multiplicities, where observed, were measured by the single frequency off resonance (SFOR) method in the case of the JEOL FX90Q or FX100, and on the BRUKER 300 by using the DEPT pulse sequence. The nucleoside numbering system used in the NMR analysis is shown in the case of the parent nucleoside in Figure 1. ^{31}P NMR spectra were obtained with a BRUKER 300, operating at 121 MHz, and measuring downfield from 85% H_3PO_4 as external reference, downfield values being positive. Microanalyses were determined by the Australian

- 21 -

Microanalytical Service, Melbourne. Pyridine was distilled from potassium hydroxide, and stored over 5A molecular sieves. Acetonitrile and methanol were dried over 3A molecular sieves. Triethylamine was
5 distilled from calcium hydride and stored under argon. Dichloromethane used in phosphoramidite syntheses was dried over 5A molecular sieves. Tetrazole was sublimed at 0.05 mmHg at 110°C. Diisopropylamine was distilled from calcium hydride
10 and stored over 3A molecular sieves. Thin layer chromatography (tlc) was carried out on Merck analytical silica gel plates (Merck No. 5735) using the following solvent systems: S1, CH₂Cl₂/MeOH (90:10 v/v), S2, CH₂Cl₂/MeOH (98:2 v/v) or S3,
15 CH₂Cl₂/EtOAc/Et₃N (45:45:10 v/v). Melting points were determined in open ended capillaries on an Electrothermal Melting Point Apparatus.

EXAMPLE 1: Synthesis of Nucleoside Analogues

3',5'-Di-O-p-toluoyl-5-iododeoxyuridine (1):

20 The title compound was prepared by a modification of the method of Robins *et al.*¹⁸ using 5-iododeoxyuridine instead of deoxyuridine, in 92% yield, mp 205-206°C (lit¹⁴ 195-196). ¹³C NMR (CDCl₃, 25 MHz) δ 21.7 (CH₃), 38.7 (C-2'), 64.1 (C-5'), 69.0
25 (C-5), 74.9 (C-3'), 83.4 (C-1'), 85.8 (C-4'), 126.1, 126.4 (tol C-1), 129.3, 129.5, 129.8 (tol C-2, C-3, C-5 and C-6), 143.6 (C-6), 144.6 (tol C-4) 149.2 (C-2), 159.7 (C-4), 166.0 (tol C-0).

3-tert-Butyloxycarbonylamidopropyne:

30 To 200 mL of CH₂Cl₂ was added 2.75 g (50 mmol) of 3-aminopropyne, followed by 10.92 g (50 mmol) of di-tert-butylpyrocarbonate. After stirring for 3 h, the reaction mixture was evaporated to a syrup, and kept at -20°C to crystallize. The product

- 22 -

was filtered off, washed with hexane and dried to give 5.34 g (69%), mp 42-44°C (lit¹³ mp 43°C).

¹H NMR (CDCl₃, 90 MHz) δ 1.46 (9H, s, CH₃), 2.21 (1H, t, J=2.6 Hz, C=CH), 3.91 (2H, dd, J=2.6 Hz and 3.5 Hz, CH₂) 4.68 (1H, br s, NH). ¹³C NMR (CDCl₃, 22.5 MHz) δ 28.4 (CH₃), 30.6 (CH₂), 71.2 (C-1), 80.1 (C(CH₃)₃), 80.2 (C-2), 155.3 (C=O).

5-(3-tert-Butyloxycarbonylamidoprop-1-ynyl)-3',5'-di-O-p-toluoyldeoxyuridine (2):

To 500 mL of deoxygenated ethyl acetate was added 5.90 g (10 mmol) of 3',5'-di-O-p-toluoyl-5-iododeoxyuridine (1), followed by 3.10 g (20 mmol) of N-BOC-3-aminopropyne, 150 mg of (Ph₃P)₂PdCl₂, 150 mg of CuI and 6.7 mL of triethylamine (50 mmol). The resulting suspension was stirred at room temperature, and the reaction followed by tlc (S2).

After 90 h, the starting material had disappeared. A further 200 mL of ethyl acetate was then added, and the resulting solution was washed with 5% disodium EDTA/H₂O (2 x 300 mL), H₂O (300 mL) and brine (300 mL). It was then dried (Na₂SO₄), the solvent evaporated, and the residue redissolved in 15 mL of solvent S3 and purified by flash chromatography¹³ using the same solvent, yield 5.08 g (84%). A sample was recrystallized from CHCl₃/MeOH 1:5 to give 2: mp 169.5 - 170.5°C.

UV(MeOH) λ_{max} 290(sh), 283, 237 nm (ε 11800, 12400, 39800), λ_{min} 263 nm (ε 5900). ¹H NMR (CDCl₃, 90 MHz) δ 1.44 (9H, s, C(CH₃)₃), 2.42 (6H, s, tol CH₃), 2.7 (2H, m, H₂'), 3.97 (2H, d, J=5.1 Hz, Hg), 4.6-4.7 (4H, m, H₄', H₅' and BOC NH), 5.6 (1H, m, H₃'), 6.4 (1H, m, H₁'), 7.26 (4H, d, J=8.1 Hz, tol H₃ and H₆), 9.16 (1H, m,

- 23 -

H_3'), 6.4 (1H, m, H_1'), 7.26 (4H, d, $J=8.1$ Hz, tol H_3 and H_6), 9.16 (1H, s, ring NH). ^{13}C NMR (CDCl₃, 22.5 MHz) δ 21.7 (q, tol CH₃), 28.4 (q, C(CH₃)₃), 31.4 (t, C-9), 38.6 (t, C-2'), 64.1 (t, C-5'), 73.8 (s, C-8), 74.9 (d, C-3'), 80.0 (s, C(CH₃)₃), 83.4 (d, C-1'), 86.1 (d, C-4'), 90.3 (s, C-7), 100.2 (s, C-5), 126.4 and 126.6 (2s, tol C-1), 129.3 - 129.9 (4s, tol C-2, C-3, C-5 and C-6), 141.9 (d, C-6), 144.5 (s, tol C-4), 149.2 (s, C-2), 155.3 (s, BOC C=O), 161.7 (s, C-4), 166.04 and 166.15 (2s, tol C=O). Anal. Calcd for C₃₃H₃₅O₉N₃: C, 64.17; H, 5.71; N, 6.80. Found: C, 63.94; H, 5.52; N, 6.55.

5-(3-tert-Butyloxycarbonylamidoprop-1-ynyl)-5'-O-

15 dimethoxytrityldeoxyuridine (5):

To a stirred suspension of 304 mg (2.2 mmol) of dry K₂CO₃ in 5 mL of dry methanol was added 617 mg (1 mmol) of 2. After 1.5 h the reaction mixture then filtered, and the filtrate neutralized with Dowex 50-X8(H⁺), the resin filtered off, and the filtrate evaporated to dryness to give 4. The product was thoroughly dried by coevaporation with dry pyridine (3 x 5 mL) and redissolved in 5 mL of dry pyridine. 406 mg (1.2 mmol) of 4,4'-dimethoxytrityl chloride was added, and the mixture was stirred for 4 h at room temperature, after which time the reaction was judged complete by tlc (S1). 2 mL of MeOH was added, the solution was stirred for a further 10 min, evaporated, redissolved in 30 mL of dichloromethane, washed with 10% NaHCO₃/H₂O (30 mL), brine (30 mL), and dried (Na₂SO₄). The solvent was again evaporated and the product redissolved in 5 mL of CH₂Cl₂ and purified by flash chromatography, eluting first with 300 mL of 2%

- 24 -

MeOH/CH₂Cl₂ and then with 10% MeOH, CH₂Cl₂.

The fractions containing the product were pooled and evaporated to dryness to give 468 mg (68% from 2) of

5. UV(MeOH) λ_{\max} 294(sh), 283, 231 nm (ϵ 6100,

5 6800, 21500), λ_{\min} 257 nm (2500). ¹H NMR

(CDCl₃, 100 MHz) δ 1.39 (9H, s, BOC CH₃), 2.4

(2H, m, H₂'), 3.38 (2H, m, H₅'), 3.78 (8H, s,

OCH₃ plus H₉), 4.1 (1H, m, H₄'), 4.6 (3H, m,

H₃' + BOC NH), 6.32 (1H, t, H₁'), 6.80, 6.89 (4H,

10 d, J=9.0 Hz, meta CH of PhOCH₃), 7.2-7.5 (9H, m,

including a doublet at 7.29, 7.34 (J=9.0 Hz) of ortho

CH of PhOCH₃, and Ph), 8.11 (1H, s, H₆). Anal.

Calcd for C₃₈H₄₁O₉N₃: C, 66.75; H, 6.04; N, 6.15.

Found: C, 66.89; H, 5.82; N, 6.00.

15 The nucleoside 4 was also purified by flash chromatography (20% MeOH/CH₂Cl₂ as eluant) of the crude reaction mixture from the deprotection reaction, after filtration of the potassium carbonate. This gave 4, ¹H NMR (d₆-DMSO, 100

20 MHz) δ 1.39 (9H, s, CH₃), 2.1 (2H, m, H₂'),

3.35 (6H, s, 2 molecules of methanol present in the

sample), 3.6 (2H, m, H₅'), 3.8 (1H, m, H₄'), 3.93

(2H, d, J=5.9 Hz, H₉), 4.2 (1H, m, H₃'), 5.10

(1H, t, J=5 Hz, 5'-OH), 2.25 (1H, d, J=4 Hz, 3'-OH),

25 6.11 (1H, t, J=6.6 Hz, H₁'), 8.14 (1H, s, ring NH);

UV (MeOH) λ_{\max} 290, 231 nm (ϵ 12900, 18200),

λ_{\min} 254 nm (ϵ 4200), at 260 nm, ϵ = 5800

M⁻¹.

30 5-(3-tert-Butyloxycarbonylamidoprop-1-ynyl)-5'-O-di-methoxytrityl-3'-N,N-diisopropylaminomethoxyphosphinyl-deoxyuridine (7):

To an argon flushed 25 mL round bottomed flask was added a solution of 243 mg (0.5 mmol) of 5, in 5 mL of dry CH₂Cl₂. This was followed by 17.5 mg

- 25 -

(0.25 mmol) of tetrazole and 25 μ L (0.25 mmole) of dry diisopropylamine. The solution was stirred until the tetrazole dissolved. 300 μ L (1.1 mmol) of bis(diisopropylamino)methoxyphosphine¹⁷ **6** was then
5 added, and the reaction followed by tlc (S3). After 5 h, the reaction mixture was washed with 10% $\text{NaHCO}_3/\text{H}_2\text{O}$ (2 x 25 mL), brine (2 x 25 mL), and dried (Na_2SO_4). The solvent was evaporated to give 392 mg (93% crude yield) of **7**. The ³¹P NMR
10 spectrum of this material showed a major peak comprised of a doublet at 150.19 and 150.45 ppm and minor peaks at 4.23 and 10.41 ppm. These by-products do not interfere with the coupling reaction.

Some of this material was purified by flash
15 chromatography (S3). ¹H NMR (CD_3CN , 100 MHz) δ 1.13 (12 H, 2d, $J=6.5$ Hz, $\text{CH}(\text{CH}_3)_2$), 1.38 (9H, s, BOC CH_3), 2.4 (2H, m, H_2'), 3.2 - 3.5 (5H, m containing 2d ($J=13.3$ Hz, PCH_3) and H_5'), 3.5 (2H, m, $\text{CH}(\text{CH}_3)_2$), 3.7-3.8 (8H, m containing one
20 strong singlet at 3.77 (trityl OCH_3) and H_9), 4.1 (1H, m, H_4'), 4.6 (1H, m, H_3'), 6.1 (1H, dt, H_1'), 6-8-7.5 (13H, m, trityl CH), 7.90 and 7.91 (1H, 2s, H_6).

25 5-(3-Aminoprop-1-ynyl)-3'5'-di-O-p-toluoyldeoxy-uridine, trifluoroacetate salt (8):

To 20 mL of 95% $\text{CF}_3\text{CO}_2\text{H}/\text{H}_2\text{O}$ (TFA/ H_2O) was added 3.09 g (5 mmol) of **2**. After being stirred for 10 min, the solvent was evaporated to dryness. 10 mL of ethyl acetate was then added, it was evaporated
30 again, the product crystallized and was filtered and dried to give 2.56 g (81%) of **8**, mp 120°C (dec). UV(MeOH) λ_{max} 290(sh), 282, 236 nm (ϵ 11900, 12400, 41200), λ_{min} 263 nm (ϵ 9000). ¹H NMR (90 MHz, d_6 -DMSO) δ 2.39 (6H, s, CH_3), 2.5-2.6

- 26 -

(m, solvent plus H_2'), 3.7 (m, H_2O impurity in solvent plus H_9), 4.6 (3H, m, H_4' and H_5'), 5.6 (1H, m, H_3'), 6.24 (1H, t, H_1'), 7.34 (4H, 2d, $J=8.1$ Hz, tol H_2 and H_6), 7.90 (4H, 2d, $J=8.1$ Hz, tol H_3 and H_5), 8.07 (1H, s, H_6), 8.3 (3H, bs, NH_3^+), 11.80 (1H, s, ring NH). ^{13}C NMR (75 MHz, d_6 -DMSO) δ 21.2 (CH_3), 29.0 (C-9), 36.4 (C-2'), 64.2 (C-5'), 74.4 (C-3'), 78.5 (C-8), 81.5 (C-1'), 85.2 (C-7), 85.7 (C-4'), 97.6 (C-5), 126.4 (tol C-1), 129.3, 129.5 (tol C-2, C-3, C-5 and C-6), 143.9 (C-6), 144.8 (tol C-4), 149.3 (C-2), 161.3 (C-4), 165.2 (carboxyl), 165.6 (tol C=O). Anal. Calcd for $C_{30}H_{28}O_9N_3F_3$: C, 57.05; H, 4.47; N, 6.65; F, 9.02. Found: C, 57.12; H, 4.75; N, 6.42; F, 9.1.

6-tert-Butyloxycarbonylamido hexanoic acid:

To 13.12 g (100 mmol) of 6-aminohexanoic acid in 400 mL of dioxan at $0^\circ C$ was added 100 mL of 1 M NaOH, and 24.01 g (110 mmol) of di-tert-butyl-pyro-
 20 carbonate. The resulting suspension was stirred at room temperature for 3 days, after which time it gave a negative ninhydrin test. The volume was then reduced under pressure to 100 mL, the mixture cooled to $0^\circ C$, covered with ethyl acetate, and acidified
 25 with 1 M $KHSO_4$ to pH 2-3. The product was extracted with ethyl acetate (3 x 150 mL), the organic phase washed with H_2O (2 x 300 mL), dried (Na_2SO_4) and evaporated to a thick syrup. This was recrystallized from ethyl acetate/ hexane, to
 30 give 20.40 g (88%), mp $39-41^\circ C$ (lit¹⁴ mp $39.5^\circ C$).

p-Nitrophenyl 6-tert-butyloxycarbonyl-amido hexanoate (9):

To a solution of 2.31 g (10 mmol) of

- 27 -

6-tert-butyloxycarbonylamidohexanoic acid and 1.62 g (12 mmol) of p-nitrophenol in 30 mL of EtOAc at 0°C was added dropwise 2.06 g (10 mmol) of dicyclohexycarbodiimide. This solution was stirred at 0°C for 0.5 h, and then at room temperature for 3.5 h, filtered to remove the dicyclohexylurea, evaporated to dryness and the product recrystallized from 95% EtOH containing 1% acetic acid, to give 3.35 g (95%) of **9**, mp 119-120°C (lit¹⁴ mp 116.5°C).

10 5-[N-(6-tert-Butyloxycarbonylamidohexanoyl)-3-amino-prop-1-ynyl)]-3',5'-di-O-p-toluoyldeoxyuridine (10):

To a solution of 1.89 g (3 mmol) of **8** in 30 mL of dry DMF was added 443 µL of DBU (3 mmol) and 1.16 g (3.3 mmol) of **9**. After being stirred for 1 h, the mixture was evaporated under vacuum, the residue redissolved in 50 mL of CH₂Cl₂ and 400 mL of ethyl acetate, washed with H₂O (2 x 300 mL), brine (300 mL), dried (Na₂SO₄), and evaporated to dryness. The solid was recrystallized from methanol to give 1.76 g (80%) of **10**, mp 192-194°C. UV(MeOH) λ_{max} 290 (sh), 282, 237 nm (ε 13800, 14400, 43000), λ_{min} 262 nm (ε 10300). ¹H NMR (CDCl₃, 100 MHz) δ 1.4-1.9 (15H, m with s at 1.43 (BOC CH₃) and H₃", H₄" and H₅"), 2.16 (2H, 5, J=7.5 Hz, H₂"), 2.42 (6H, s, tol CH₃), 2.75 (2H, m, H₂'), 3.1 (2H, m, H₆"), 4.04 (2H, d, J=5.0 Hz, H₉), 4.5-4.8 (4H, m, H₄' , H₅' and BOC NH), 5.6 (1H, m, H₃'), 6.31 (1H, dd, H₁'), 7.27 (4H, d, J=8.2 Hz, tol H₃ and H₅), 7.84 (1H, s, H₆), 7.91 and 7.93 (4H, 2d, J=8.2 Hz, tol H₁ and H₆), 9.0 (1H, br s, ring NH). ¹³C NMR (CDCl₃, 75 MHz) δ 21.7 (tol CH₃), 25.2 (C-4"), 26.4 (C-3"), 28.4 (BOC CH₃), 29.7 (C-5"), 30.0 (C-9), 36.1 (C-2"),

- 28 -

38.6 (C-2'), 40.4 (C-6"), 64.2 (C-5'), 74.0 (C-8),
 74.8 (C-3'), 79.8 (C(CH₃)₃), 83.4 (C-1'), 86.0
 (C-4'), 89.9 (C-7), 100.0 (C-5), 126.2, 126.4 (tol
 C-1), 129.3, 129.5, 129.6 and 129.8 (tol CH), 142.1
 5 (C-6), 144.8 (tol C-4), 149.1 (C-2), 156.1 (BOC C=O),
 161.9 (C-4), 166.0, 166.2 (tol C=O), 172.3 (C-1").
 Anal. Calcd for C₃₉H₄₆O₁₀N₄: C, 64.10; H,
 6.34; N, 7.67. Found: C, 64.34; H, 6.32; N, 7.51.

5-[N-(6-tert-Butyloxycarbonylamidohexanoyl)-3-
 10 amino-prop-1-ynyl)]-5'-O-dimethoxytrityldeoxyuridine
(12):

The title compound was prepared from 10 using the
 same method as that used to prepare 5 from 2. Yield
 1.20 g (75% from 10). UV(MeOH) λ_{\max} 293(sh) 283,
 15 233 nm (ϵ 8500, 9000, 24500), λ_{\min} 257 nm (ϵ
 2900). The ¹H NMR spectrum of this compound was a
 composite of those resonances arising from the
 deoxyribose part of 5 and those from the heterocyclic
 base part of 10. ¹³C NMR (CDCl₃, 75 MHz) δ
 20 25.1 (C-4"), 26.4 (C-3"), 28.4 (C(CH₃)₃), 29.7
 (C-5"), 30.0 (C-9), 35.9 (C-2"), 40.4 (C-6"), 41.7
 (C-2'), 55.3 (OCH₃), 63.6 (C-5'), 72.2 (C-3'), 74.1
 (C-8), 79.2 (C(CH₃)₃), 86.0 (C-4'), 86.8 (C-1'),
 87.0 (trityl central C), 89.7 (C-7), 99.5 (C-5),
 25 113.4 (methoxyphenyl C-3 and C-5), 127.0, 127.9 and
 128.1 (phenyl CH), 130.0 (methoxyphenyl C-2 and C-6);
 135.6 (methoxyphenyl C-1), 143.1 (C-6), 144.6 (phenyl
 C-1), 149.4 (C-2), 156.0 (BOC C=O), 158.6
 (methoxyphenyl (C-4), 162.5 (C-4), 172.7 (C-1").
 30 Anal. Calcd for C₄₄H₅₂O₁₀N₄: C, 66.32; H,
 6.58; N, 7.02. Found: C, 65.94; H, 6.52; N, 6.70.

- 29 -

5-[N-(6-tert-Butyloxycarbonylamidohexanoyl)-3-amino-prop-1-ynyl]-5'-O-dimethoxytrityl-3'-N,N-di-isopropyl-aminomethoxyphosphinyldeoxyuridine (11):

The preparation of 11 was similar to that of 7, except that the reaction was allowed to proceed for 4 h, and a further 30 mL of CH_2Cl_2 was added to the reaction mixture before the washes. The washed and dried solution was evaporated to dryness under vacuum, to give 903 mg (94% crude yield) of 11.

³¹P NMR of this material showed a major peak at 149.86 ppm, with minor peaks at 7.35, 13.06 and 18.25 ppm.

EXAMPLE 2:

Coupling of phosphoramidites 7 and 11 to the 5'-hydroxyl of an oligonucleotide:

The methods used to add the modified nucleoside phosphoramidites to the 5'-end of a fully protected, solid support bound oligonucleotide were standard²⁰. The fully protected resin-bound oligonucleotide was synthesized on the Applied Biosystems 380A DNA Synthesizer, on a 1 μmole scale. The solid support was then transferred to a manual reaction cell. This cell was similar to a miniature chromatography column, 1 cm in diameter and 3 cm long, with a B14 quick-fit top and a medium porosity sintered glass disc with a 3-way teflon tap at the bottom. Following detritylation (3% dichloroacetic acid/ CH_2Cl_2), the resin was washed thoroughly with dry CH_3CN , and left under argon.

10 μmole of the phosphoramidite and 40 μmole of tetrazole were then added, followed by 1 ml of dry CH_3CN . The cell was shaken for 15 min, drained, and the phosphite triesters oxidized with 0.1 M iodine solution in the usual way. A trityl assay was

- 30 -

carried out on a small sample to quantify the extent of reaction. Following removal of the methyl protecting groups on phosphate (thiophenoxide ion, 2h), the resin was treated with 90% TFA/ethanedithiol for 5 min, drained, washed thoroughly with CH_3CN , with a total of 20 mL at 20% $\text{Et}_3\text{N}/\text{CH}_2\text{Cl}_2$, and then again with CH_3CN and dried. The oligonucleotide was then cleaved from the support with 35% aqueous NH_3 (4 mL), and the resulting solution kept at 55°C overnight to remove the base protecting groups. Evaporation to dryness gave the product which was redissolved in H_2O (3 mL).

The oligonucleotides were purified by polyacrylamide gel electrophoresis. The product was the slowest moving major band, running at ~1-2 nucleotides slower than the underivatized oligonucleotide. Typically, ~150 μL of the oligonucleotide solution was purified on a 10%, 1.5 mm thick, 20 cm long polyacrylamide gel (25 μL + 5 μL formamide per 1 cm x 1 cm well). The bands were visualized by UV shadowing, using a fluorescent tlc silica gel sheet as background. The product bands were cut out, eluted in H_2O , dialysed, lyophilized, and redissolved in 150 μL of H_2O .

25 **EXAMPLE 3:**

Preparation of oligonucleotides containing internal modified nucleotides:

The nucleotide phosphoramidites 7 and 11 were used on the Applied Biosystems DNA synthesizer to prepare oligonucleotides that had their thymidine residues replaced by one or the other of the modified nucleosides. The phosphoramidites were made to either 0.1 M (for 7) or 0.15 M (for 11) in dry acetonitrile. The syntheses were carried out on a

- 31 -

0.2 μ mole scale. The repetitive coupling yields were 99-100%. Following chain assembly, the solid support was transferred to a manual reaction cell and then deprotected and cleaved from the solid support
5 as in the case of the oligonucleotides containing the single 5' modified nucleoside. The final product was redissolved in 2 mL of H_2O .

EXAMPLE 4:**Dye conjugation to the amino oligonucleotide:**

10 The following procedure was used for the conjugation of FITC to the purified oligonucleotide containing a single modified nucleoside at the 5' end. To a solution of 2 mg (5 μ mol) of FITC in 20 μ L of DMF was added 180 μ L of 0.1 M K_2HPO_4 ,
15 pH 9.0, mixed, and then 100 μ L (~30 nmol) of the amino oligonucleotide solution. The mixture was kept in the dark overnight, and then applied to a 10 mL column of Sephadex G-25 (medium) in 0.1 M ammonium acetate, pH 9.0. 0.5 mL fractions were collected,
20 and the fluorescent material (detected by illuminating with a UV lamp) eluting in the excluded volume was collected. This was freeze dried, redissolved in 200 μ L of 0.1 M ammonium acetate, pH 9.0 buffer, and reapplied to another, similar column
25 of Sephadex G-25. The fluorescent fractions were collected as before, pooled and the absorbances at 260 and 495 nm read. From this ratio, the number of fluorescein residues per oligonucleotide molecule was determined using ϵ_{260} for the modified KPIB and
30 H₂CAL (see results section for the nucleotide sequences of these oligonucleotides) of 3.2×10^5 and $4.4 \times 10^4 M^{-1}$ respectively, and ϵ_{495} for fluorescein of $7 \times 10^4 M^{-1}$. The product was then lyophilized, and re-lyophilized twice from H_2O .

- 32 -

For the conjugation of FITC to oligonucleotide with multiple internal amino groups a much larger excess of FITC was used. To a solution of 26 mg (63 μ mole) of FITC in 100 μ L of DMF was added 100 μ L of 1.0 M K_2HPO_4 pH 9.0, mixed, and then 100 μ L (~10 nmol) of the amino oligonucleotide. This was left to react overnight in the dark. It was purified as in the previous case, and the fluorescein loading determined, using ϵ_{260} for the modified KPIB and HCAL of 3.1×10^5 and $4.3 \times 10^5 M^{-1}$ respectively, and taking into account the absorbance of fluorescein at 260 nm, using ϵ_{260} for fluorescein of $2 \times 10^4 M^{-1}$.

EXAMPLE 5:**15 Hybridization with FITC-labelled oligonucleotides:**

RNA dot blots with polyadenylated RNA derived from mouse salivary glands were prepared as previously described¹⁵. The amount of RNA decreased by a factor of 3 on each successive dot, starting from an initial value of 1 μ g. The nitrocellulose filters were prehybridized for 4 h at 42°C in a solution of 5xSSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate, pH 6.5, 0.02% bovine serum albumin, Fraction V, 0.02% Ficoll, 0.02% polyvinylpyrrolidone, 30 μ g/ml denatured calf thymus DNA, 50% formamide. Hybridizations were performed under four different sets of conditions: high stringency, hybridization at 40°C for 24 h, and washing with 2xSSC at room temperature; intermediate stringency, as above but hybridizing at room temperature; low stringency, as above but hybridization mixture containing 10% formamide instead of 50%; and lowest stringency, prehybridizing

- 33 -

at 4°C, hybridizing at 4°C with no formamide present, for 5 days, and washing at room temperature with 2xSSC.

RESULTS

5 Preparation of C-5 substituted nucleotides:

The approach used for the preparation of the substituted deoxyuridines is shown in Figure 2. 3',5'-di-O-p-toluoyl-5-iododeoxyuridine (1), prepared from the commercially available 5-iododeoxyuridine, 10 was condensed with N-BOC-3-aminopropyne, in the presence of catalytic amounts of bis(triphenylphosphine)palladium chloride and cuprous iodide. Robins and Barr have reported this coupling of terminal alkynes with 5-iodouracils and 15 5-iododeoxyuridines, using alkynes with alkyl, either or ester substituents¹⁸. The reactions were carried out in triethylamine as the solvent, at 50°C. We tried a variety of conditions to maximise the yield of the product 2, and minimize the yield of 20 the major by-product, a fluorescent nucleoside which, by analogy with the work of Robins and Barr, probably has the structure 3. The conditions that we found to give the best yield of 2 were using ethyl acetate as solvent, with a five-fold molar excess of 25 triethylamine over 1, and carrying out the reaction at room temperature. this gave a yield of 84%. The structure of the product was confirmed by ¹H and ¹³C NMR spectroscopy. This product is a key compound, from which a number of other derivatives 30 can be obtained.

The phosphoramidite 7 was prepared from 3 by a three step procedure, as shown in Figure 3. The 3',5' ester protecting groups of 2 were removed using potassium carbonate/methanol and the resulting

- 34 -

product 4 treated with dimethoxytrityl chloride in pyridine to give 5. The UV spectrum of 4 also provided evidence for the structure of the nucleoside. The absorption maximum of the heterocyclic base shifted from 265 nm in thymidine, to 290 nm in the nucleoside 4, with an accompanying increase in its intensity. This shift in the absorption maximum is seen in all of the derivatives synthesized that contain this chromophore.

10 Treatment of the 5'-tritylated nucleoside 5 with a two-fold excess of the bis(dialkylamino)phosphine 6, under catalytic conditions, gave the phosphoramidite 7. This method of phosphoramidite preparation is similar to that reported by Caruthers
15 et al¹⁰ for the preparation of phosphoramidites in situ.

EXAMPLE 6

Preparation of nucleosides with a longer linker arm on C-5:

20 Even though 7 can be used to introduce internal primary aliphatic amino groups in an oligonucleotide, as will be described later in this report, it was surmised from the outset that the short length of the linker arm between the heterocyclic base and the site
25 of attachment of the label (the end amino group) might influence the hybridization properties of the oligonucleotides. This would be especially the case if fluorescent moieties were to be attached since these tend to be large, planar molecules. A strategy
30 was thus developed to introduce a longer linker arm on C-5. This is outlined in Figure 4. The key compound 2 had its amino group deprotected with 95% TFA/H₂O, to give 8 in high yield. This was then allowed to react with the p-nitrophenyl ester 9, in

- 35 -

the presence of one equivalent of 1,8-diazabicyclo-[5.4.0]undec-7-ene (DBU), to give the adduct 10 in high yield. This product was converted into the phosphoramidite 11 in a similar manner to that
5 described for 2.

EXAMPLE 7:**Incorporation of modified nucleosides on the 5'-end of oligonucleotides:**

Initially, phosphoramidites 7 and 11 were tested
10 by coupling them, manually, to the 5'-end of a preassembled oligonucleotide. Thus, the 30mer GGGCTTCACAACATCTGTGATGTCAGCAGG was assembled on an automated Applied Biosystems 380A DNA Synthesizer, and left on the resin, fully protected. This
15 sequence is complementary to a region of the kallikrein mRNA that is common to all the kallikreins¹⁵ and will be referred to as KPIB. The resin was transferred to a manual reaction cell. After detritylation of the last nucleoside, either 7
20 or 11 was coupled, in the presence of tetrazole. The couplings were essentially quantitative, as assayed by the trityl test. After removal of the phosphate protecting groups with thiophenoxide ion, the resin was treated with 90% TFA:10% ethanedithiol for five
25 minutes, in order to remove the BOC protecting group. The presence of ethanedithiol protected with oligonucleotide from degradation. Triethylamine was used to neutralize the newly formed amino group and the secondary phosphates, and the oligonucleotide was
30 then treated in the normal way to cleave it from the resin and remove the base protecting groups. The oligonucleotides were purified by polyacrylamide gel electrophoresis, with the modified oligonucleotides running one to two nucleotides slower than the normal

- 36 -

KPIB.

Internal incorporation of modified nucleosides
in oligonucleotides:

Having established that the phosphoramidites 7
5 and 11 will couple as normal, we proceeded to
synthesize oligonucleotides that incorporated these
two modified nucleosides internally. The syntheses
were carried out automatically on the Applied
Biosystems DNA Synthesizer. Each of the
10 phosphoramidites was used to synthesize two different
oligonucleotides, one being KPIB, and the other the
40mer AGGTGCTCCAACCCCAATTGCAGTTTGGGGGAACGTGTGA
(HCAL). HCAL is complementary to part of the mRNA
for human calcitonin and has been used to detect this
15 mRNA in tissue sections¹⁶. The sequences were
synthesized as shown, except that every thymidine
residue was replaced with one of the modified
nucleosides. the repetitive coupling yields were in
the order of 99-100%. Following chain assembly, the
20 oligonucleotide was treated sequentially with
thiophenoxide ion, 90% TFA/ethanedithiol, cleaved
from the solid support with concentrated ammonia
solution and treated at 50°C for 15 hr to remove the
base protecting groups. When an attempt was made to
25 analyse this product by polyacrylamide gel
electrophoresis, no material could be seen on the gel
by the normal method of UV shadowing. It appears
that the presence of the amino groups, which would be
charged at the pH of the gel medium, changes the
30 electrophoretic properties of the oligonucleotide.
Consequently, it was used in the next step without
further purification. The repetitive coupling yields
however are high, so that only a small amount of

- 37 -

shorter sequences would be expected to be present in the product.

EXAMPLE 8:**Coupling of fluorophores to the amino-****oligonucleotides:**

The procedure used for the attachment of amine reactive fluorophores to amino-oligonucleotides is basically the same as that which has been widely used to attach such molecules to the ϵ -amino groups of lysine residues in proteins¹⁷. The procedure involves the reaction of the amino-oligonucleotide with the reactive fluorophore, at pH 9, so that a significant portion of the aliphatic amino groups are not protonated. Smith *et al.* used a similar procedure in coupling fluorophores to 5'-aminothymidine containing oligonucleotides¹. The labelling reaction mixture is put through a Sephadex G-25 column twice, to separate the excess unreacted dye from the oligonucleotide. The extent of labelling is subsequently determined by measuring the absorption of the product at 260 nm and at 495 nm. With the oligonucleotides containing the nucleotide from 7 (short C-5 arm) at the 5'-end, a single reaction using a 150 fold molar excess of FITC labelled 20% of the kallikrein oligonucleotide molecules and one third of the calcitonin ones. A second FITC coupling reaction on the same material increased the labelling to 67% and 83% respectively. This labelled material was also 5'-end labelled with [λ -³²P]ATP and subjected to electrophoresis. It showed a single radioactive band, at the expected position (data not shown).

The oligonucleotides containing the multiple internal primary aliphatic amino groups, and thus

- 38 -

multiple potential sites of label incorporation were also subjected to the FITC coupling reaction. Firstly, the oligonucleotides containing the short C-5 arm are labelled. The kallikrein probe, containing seven potential sites of label incorporation, contained a single fluorescein per oligonucleotide molecule when the same labelling reaction as before was used, and the calcitonin probe, containing nine potential sites, contained 1.5 molecules of label. When the procedure was changed to using a much larger excess of FITC (900 fold), the level of incorporation was increased to 4.1 for KPIB and 7.2 for HCAL. These figures were calculated taking into account the absorbance of fluorescein at 260 nm, since this becomes significant when a number of fluorophores are attached to the oligonucleotide molecule. Repeating the reaction did not have any significant effect on the extent of labelling. In a test reaction, when normal KPIB was subjected to the labelling reaction with the large excess of FITC, it was found that a background level of labelling of 1 in 110 nucleotides was obtained. This compared with 15 per 110 nucleotides for the corresponding amino-oligonucleotides.

When the kallikrein oligonucleotide containing the nucleotide from 11 (long C-5 arm) at the 5'-end was labelled with a 900 fold excess of FITC, a single reaction gave complete incorporation of the label. This fluorescent product was also radioactively labelled at the 5'-end, and it gave a single band upon gel electrophoresis, at the expected position (data not shown).

When the oligonucleotides containing the multiple internal nucleotide substitutions carrying the long

- 39 -

C-5 arm were subjected to the FITC coupling reaction, as before (large excess of FITC), the level of incorporation of label was 2.7 for KPIB and 5.2 for HCAL. These multi-labelled probes were also 5'-end labelled with (λ - ^{32}P)ATP. Purification of the product mixture from the reaction on Sephadex G-25 gave a radioactive high molecular weight peak; however, on gel electrophoresis no radioactive band was seen.

10 **EXAMPLE 9:**

Hybridization with the labelled oligonucleotides:

The kallikrein oligonucleotides were tested for their ability to hybridize to mouse salivary gland poly(A)⁺ mRNA, which is rich in kallikrein message¹⁵. Poly(A)⁺ mRNA was spotted on nitrocellulose filters, at varying concentrations, from 1 μg /per dot downwards. The fluorescent oligonucleotides were then 5'-end ^{32}P labelled in the normal way and were used to probe the nitrocellulose filters. When the fluorescent oligonucleotides containing the short linker arm were used to probe the nitrocellulose filters, at high stringency, no signal was seen. However, when the conditions of intermediate stringency were used, the 5'-singly labelled probe gave a signal equal in intensity to that given by the normal unmodified probe (Figure 5), whereas the multi-labelled probe still did not give any appreciable signal. When hybridizing under conditions of low and lowest stringency with the multi-labelled probe, the signal was ten times and three times less intense than that of the normal probe respectively.

These results also show that it is not a

- 40 -

contaminating small amount of normal probe that is given rise to the hybridization signal, but the fluorescently labelled probe itself, otherwise a signal would be seen with the more stringent

5 hybridization conditions as well.

When the fluorescent oligonucleotides containing the C-5 arm were hybridized, the singly labelled probe hybridized as well as the normal probe, under the high stringency conditions (Figure 6). The
10 multiply labelled probe, under these same conditions, gave a signal that was approximately three times weaker.

The specificity of hybridization of the fluorescently labelled oligonucleotides was also
15 checked. Figure 7 shows the results of hybridization under conditions of intermediate stringency, of the two singly labelled (short and long arms) kallikrein oligonucleotides with liver mRNA and tRNA as compared to salivary gland mRNA. No visible signal is seen in
20 the case of the non-kallikrein RNA containing nucleic acids indicating that the hybridization is specific to the kallikrein mRNA containing species.

25

30

- 41 -

REFERENCES:


1. Smith, L.M., Fung, S., Hunkapiller, M.W.,
Hunkapiller, T.J., and Hood, L.E. (1985) Nucleic
5 Acids Res. 13, 2439-2502.
2. Jablonski, E., Moomaw, E.W., Tullis, R.H. and
Ruth, J.L. (1986) Nucleic Acids Res. 14,
6115-6128.
- 10 3. Ruth, J.L. (1984) DNA 3, 123.
4. Ruth, J.L., Morgan, C. and Pasko, A. (1985) DNA
4, 93.
- 15 5. Jablonski, E. and Ruth, J.L. (1986) DNA 5, 89.
6. Greene, T.W. (1981) Protective Groups in Organic
Synthesis, John Wiley & Sons, Inc.
- 20 7. Barone, A.D., Tang, J.-Y. and Caruthers, M.H.
(1984) Nucleic Acids Res. 12, 4051-4061
8. Rigby, P.J.W., Dieckmann, M., Rhodes, C., and
25 Berg, P. (1977) J. Mol. Biol. 113: 237--251
9. Taylor, P.M., Illmensee, R., and Summers, J.
(1976) Biochim. Biophys. Acta 442: 324-330
- 30 10. Caruthers, M.H., Beaucage, S.L., Echevitim, J.W.,
Fisher, E.F., Goldman, R.A., de Hasetu, P.L.,
Manchecki, W., Matkucchi, M.D., Rosenthal, M.S.,
and Stabiusky, &. (1982) Cold Spring Harbor Sym.
Quant. Bio. 47: 411-418
- 35 11. Melton, D.A., Krieg, P.A., Rebagliati, M.R.,
Maniatis, T., Zinn, K., Green, M.R. (1984)
Nucleic Acids Res. 12: 7035-7056
- 40 12. Lowary, P., Sampson, J., Milligan, J., Groebe, D.
and Ohlenbeck, O.C. (1986) "Structure and
Dynamics of RNA, NATO ASI Series 110" pp. 69-76,
ed. van Knippeuberg, P.H. and Hilbers, C.W.,
Plenum Press, New York
- 45 13. Still, W.C., Kahn, M. and Mitra, A. (1978) J.
Org. Chem. 43, 2923-2925.
14. Tesser, G.I., Fischer, H. and Schwyzer, R.
50 (1974) Helv. Chim. Acta 57, 1718-1730.

- 42 -

15. van Leeuwen, B.J., Evans, B.A., Tregear G.W. and Richards, R.I. (1986) J. Bio. Chem. 261, 5529-5535.
- 5 16. Zajac, J.D., Penschow, J., Mason, T., Tregear, G.W., Coghlan, J.P. and Martin, T.J. (1986) J. Clin. End. Metab. 62, 1037-1043.
- 10 17. Nairn, R.C. Fluorescent protein tracing, 4th Ed., Churchill Livingstone, Edingburgh, 1976.
18. Robins, M.J. and Barr, P.J. (1983) J. Org. Chem. 48, 1854-1862.
- 15 19. Sproat, S. and Bait, M.J. (1984) Oligonucleotide Synthesis (a practical approach), Bait, M.J. ed. pp. 83-116, IRL Press, Oxford
- 20 20. Penschow, J.D., Haralambidis, J., Aldred, P., Tregear, G.W. and Coghlan, J.P. (1986) Methods in Enzymology 124, 534-548

CLAIMS:


1. A nucleoside derivative of the formula (I):



characterized in that;

Y is H or OH or a protected hydroxy group;

X is H, a phosphonate group or a phosphoramidite group of the formula



where R^1 and R^2 are the same or different, and are selected from alkyl and substituted alkyl, which may be branched or unbranched; and Q is a phosphate protecting group;

Z is H a phosphate or triphosphate group or a hydroxy protecting group;

X' is a C_{1-15} alkyl group which may be branched or unbranched;

R is an amino protecting group or a fluorophore, or other non-radioactive detectable marker; or the group Y'NHA, where Y' is an alkyl (C_{1-40}) carbonyl group which may be branched or

- 44 -

unbranched, and A is an amino protecting group or a fluorophore or other non-radioactive detectable marker.

2. A nucleoside derivative as claimed in claim 1, characterized in that R^1 and R^2 are both isopropyl groups.

3. A nucleoside derivative as claimed in claim 1 or claim 2, characterized in that X' is methylene and R is $\text{CO}(\text{CH}_2)_n\text{A}$, where A is as defined in claim 1 and n is 1 to 15.

4. A nucleoside derivative as claimed in claim 3, characterized in that n is 5.

5. A nucleoside derivative as claimed in claim 1, characterized in that:

Y is H or OH or a protected hydroxy group;

X is $\text{P}-\text{N}(\text{CH}_2(\text{CH}_3)_2)_2$
 $\quad \quad \quad |$
 $\quad \quad \quad \text{OCH}_3$

Z is dimethoxytrityl;

X' is CH_2 ; and

R is $\text{CH}_2\text{CO}(\text{CH}_2)_5\text{NHA}$, where A is as defined in claim 1.

6. A nucleoside derivative as claimed in claim 1, characterized in that:

Y is H, OH or a protected hydroxy group;

X is H;

Z is triphosphate;

X' is CH_2 ; and

R is $\text{CO}(\text{CH}_2)_5\text{NHA}$, where A is as defined in claim 1.

- 45 -

7. A nucleoside derivative as claimed in any one of claims 1 to 6, characterized in that Q is selected from methyl, phenyl, substituted phenyl, benzyl, and cyanoethyl groups.

8. A nucleoside derivative as claimed in any one of claims 1 to 7, characterized in that the non-radioactive detectable marker is selected from biotin, avidin, colloidal gold or silver and ferritin.

9. A nucleoside derivative as claimed in any one of claims 1 to 7, characterized in that the non-radioactive detectable marker is an enzyme.


10. A nucleoside derivative as claimed in claim 9, characterized in that the enzyme is β -galactosidase, urease, peroxidase or alkaline phosphatase.

11. A nucleoside derivative as claimed in any one of claims 1 to 7, characterized in that the fluorophore is fluorescein.


12. A nucleoside derivative as claimed in any one of claims 1 to 7, characterised in that the fluorophore is a fluorophore precursor which contains one or more groups which suppress fluorescence, but which is capable of fluorescence once these groups are removed.

13. A nucleoside derivative as claimed in claim 12, characterized in that it has the formula:

- 46 -




14. A method for the preparation of a nucleoside derivative of the formula (I) as stated and defined in claim 1, characterized in that it comprises reacting a 5-iodouridine or 5-iododeoxyuridine of the formula (II):



wherein X and Z are as defined in claim 1;
with an aminoalkyne having the formula $H-C\equiv C-X'NR$,
where X' and R are as defined in claim 1, in the
presence of a palladium catalyst.

15. A polynucleotide, characterized in that it
contains one or more nucleotide units of the formula
(III)

- 47 -



wherein X', Y and R are as defined in claim 1.

16. A method for the synthesis of a polynucleotide as claimed in claim 15, wherein individual nucleotides or groups of nucleotides are sequentially attached to a growing nucleotide chain, characterized in that at least one of the nucleotides is a nucleoside derivative of the formula (I) as defined in claim 1.


17. A method as claimed in claim 16 which comprises reacting together;

- (a) a first polynucleotide;
- (b) a second polynucleotide which hybridises to a portion of the first polynucleotide;
- (c) one or more nucleotide triphosphates;
- (d) a DNA polymerase or RNA polymerase;

whereby a polynucleotide is synthesised from the 3' end of said second polynucleotide, characterised in that at least one of said nucleotide triphosphates is a nucleoside derivative of the formula (I) as defined in claim 1, wherein Z is triphosphate and X is hydrogen.

- 48 -

18. A method claimed in claim 16, which comprises sequentially coupling nucleotides together through their respective 5' and 3' ends, characterised in that at least one of said nucleotides is a nucleoside derivative of the formula (I) as defined in claim 1, wherein X is selected from phosphonate or a group of the formula



wherein R^1 , R^2 and Q are as defined in claim 1.

19. A method for sequencing DNA which comprises the steps of:

- (a) providing a first reaction mixture comprising:
 - (i) a polydeoxynucleotide;
 - (ii) a polydeoxynucleotide primer capable of hybridizing to part of the polydeoxynucleotide (i);
 - (iii) dATP, dGTP, dCTP, dTTP;
 - (iv) ddATP;
 - (v) a DNA polymerase or the Klenow fragment of DNA polymerase;
- (b) providing a second reaction mixture which is the same as said first reaction mixture, except that the ddATP is replaced with ddGTP;
- (c) providing a third reaction mixture which is the same as the said first reaction mixture except that ddATP is replaced with ddCTP;
- (d) providing a fourth reaction mixture which is the same as the said first reaction mixture except that the ddATP is replaced with ddTTP;
- (e) separately incubating the said reaction mixtures to extend in each case the

- 49 -

polydeoxynucleotide primer from its 3' end to produce polydeoxynucleotides of different lengths, the number of nucleotides in each thereby newly synthesised polynucleotide being determined by the incorporation of a dideoxynucleotide into the growing chain;

(f) fractionating reaction mixtures (a) to (d) by passage through a gel matrix;

characterized in that:

the polydeoxynucleotide primer (ii) is a polydeoxynucleotide as defined in claim 13 wherein R or A is a fluorophore, or other non-radioactive detectable marker, and/or each said reaction mixture contains a nucleoside derivative of the formula (I) as defined in claim 1, wherein Z is triphosphate X is hydrogen, and R or A is a fluorophore, or other non-radioactive detectable marker; whereby the fluorophore, or other non-radioactive detectable marker, is incorporated into each newly synthesized polydeoxynucleotide;

and that the relative positions of the newly synthesized polydeoxynucleotides separated on the gel matrix are identified by detection of the fluorophore, or other non-radioactive detectable marker, carried by the newly synthesized polydeoxynucleotide, thus allowing the DNA sequence of the first polynucleotide to be elucidated.

20. A method as claimed in claim 19, wherein each newly synthesized polydeoxynucleotide contains at least one fluorophore which is detected by fluorescence induced by irradiation with a light source.

- 50 -

21. A method as claimed in claim 19 or 20, characterized in that each of reaction mixtures (a) to (d) contains a different fluorophore having different emission maxima, or a different non-radioactive detectable marker.

1/8





Fig. 1.

2/8



5(AND 6)-CARBOXYFLUOROSCEIN




Fig.2

3/8





Fig. 2A.

4/8



5/8




FIG. 4.

SUBSTITUTE SHEET

6/8




FIG. 5.

7/8




FIG. 6.

8/8






FIG. 7.



B




A

FIG. 8.

salivary gland
liver
tRNA

INTERNATIONAL SEARCH REPORT

International Application No PCT/AU 88/00207

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) According to International Patent Classification (IPC) or to both National Classification and IPC Int. Cl. ⁴ C07H 19/10, 19/06, 19/073, 23/00		
II. FIELDS SEARCHED Minimum Documentation Searched ¹ Classification System Classification Symbols IPC ⁴ C07H 19/10, 19/06, 19/073, 23/00 Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ² AU : IPC as above		
III. DOCUMENTS CONSIDERED TO BE RELEVANT³		
Category ¹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	US,A, 3870700 (KOTICK et al) 11 March 1975 (11.03.75)	(1)
A	US,A, 4211773 (LOPEZ et al) 8 July 1980 (08.07.80)	(1)
A	Derwent Abstract Accession no. 84-032852/06, Class D16, JP,A, 58-221168 (YAMASA SHOYU K.K.) 22 December 1983 (22.12.83)	(1)
A	Patents Abstracts of Japan, C-72, page 108, JP,A, 54-151987 (TOYAMA KAGAKU KOGYO K.K.) 29 November 1979 (29.11.79)	(1)
A	Patents Abstracts of Japan, C-261, page 134, JP,A, 59-163396 (YAMASA SHOYU K.K.) 14 September 1984 (14.09.84)	
A	AU,A, 60055/86 (THE WELLCOME FOUNDATION LIMITED) 15 January 1987 (15.01.87)	
A	AU,B, 69599/87 (576107) (HEINRICH MACK NACHF) 3 September 1987 (03.09.87)	
A	AU,A, 82521/87 (THE WELLCOME FOUNDATION LIMITED) 16 June 1988 (16.06.88)	
<p>¹ Special categories of cited documents, is</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search 10 October 1988 (10.10.88)		Date of Mailing of this International Search Report 18 OCTOBER 1988 (18.10.88)
International Searching Authority Australian Patent Office		Signature of Authorized Officer  D. ROWSON

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON
INTERNATIONAL APPLICATION NO. PCT/AU 88/00207

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Members			
US 4211773	AU 50757/79	CA 1131626	EP 10205		
	ES 484626	JP 55049395			
AU 60055/86	DK 3265/86	EP 208550	ES 2000323		
	GB 8517402	JP 62012793	ZA 8605130		
AU 69599/87	DE 3606634	DK 1027/87	EP 234494		
	FI 870873	HU 43614	IL 81752		
	JP 62270586	PT 84384			
AU 82521/87	CN 87108265	DK 6542/87	EP 272065		
	FI 875487	GB 8629892	JP 63165397		
	NO 875209	PT 86356			

END OF ANNEX